In 1965, Centifanto reported (1) that Escherichia coli K-12 strains infected with bacteriophage A produce an antiviral agent that is active against herpes simplex virus in vivo and in vitro and against vaccinia virus in vitro. Subsequent investigations by this author (2) suggested that this substance, which was named "phagicin," might be a phage internal protein which interferes with intracellular replication of deoxyribonucleic acid (DNA) viruses. The substance, which acted by a mechanism other than interferon induction (1), was found in both infected E. coli lysates and in disrupted, purified phage particles (2), but was reported not to be present in cultures of uninfected bacteria. By using partially purified extracts, Meek and Takahashi (6) also noted the presence of a substance which inhibited vaccinia plaque development and found no observable host cell toxicity of this substance by cell monolayer morphology and radioautography. We report here our unsuccessful efforts to confirm the production of a specific antiviral agent by phage X using a cell monolayer assay system (1, 2).
MATERIALS AND METHODS
Bacterial strains used for our experiments were W3350, W3350 (XC1857), W3350 (X+), and W1485, which have been described previously (3, 9 mental and control strains were prepared by sonication by using a Branson Sonifier at 75 W for 45 s at 4 C. The antiviral activity of the lysate was not affected by the sonication procedure (unpublished data).
Alternatively, phage lysates were produced by infection (of E. coli W1485) in liquid culture with Xb2b,c at a multiplicity of 5. The control for these experiments was the sonicated, uninfected strain. After lysis or sonication, or both, preparations were centrifuged at 10,000 rpm in the 9RA rotor of a Lourdes model A-2 centrifuge at 4 C for 10 min. The supernatant fluid was then passed through a sterile, membrane filter (0.45-aum pore size, Millipore HA or Nalge grid membrane). Dilutions were made of these extracts in the assay media described below. Phage titers obtained were 3 to 8 x 10"0 plaque-forming units (PFU) per ml. The protein concentrations of the lysates and sonically treated materials are presented in the tables.
The vaccinia plaque inhibition assay system utilized chicken embryo monolayers, which were priinarily of uniform, fibroblastic morphology, grown in 60-by 15 (Table 2 ). Although addition of bacterial cell culture medium also affected vaccinia plaque count, bacterial extracts prepared from either induced X lysogens or nonlysogenic controls resulted in greater inhibition of plaque formation than was seen after addition of bacterial culture medium alone.
DISCUSSION
We conclude from the results reported here that inhibition of vaccinia plaque formation by bacterial cell extracts is nonspecific and is unrelated to the presence of developing X phage or to the expression of X genes. When nonlysogenic, 863 The mechanism for the observed toxicity of bacterial cell extracts on chicken embryo monolayer cultures and for the nonspecific effects of both experimental and control extracts on plaque formation by vaccinia virus is unclear. However, it is possible that interferon stimulation by released polynucleotides (4) may play a role. Effects on viral absorption seem unlikely, for absorption of vaccinia virus was essentially complete before application of the bacterial extracts.
